When the curtain closed on the third quarter, 67 global private biotech companies developing biotherapeutics had successfully completed transactions in the period, according to data compiled by BioWorld Snapshots, for a combined total of approximately $1.2 million from the 63 companies that disclosed terms of their deals. That amount, however, represented a significant 33 percent drop from the $1.8 billion raised from 74 deals during the second quarter of 2014.